galantamine has been researched along with okadaic acid in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
de Los Ríos, C; Egea, J; Gálvez, E; García, AG; Iriepa, I; León, R; López, MG; Marco-Contelles, J; Moraleda, I; Romero, A; Samadi, A; Villarroya, M | 1 |
Arias, E; Gallego-Sandín, S; García, AG; López, MG; Villarroya, M | 1 |
Buendia, I; Egea, J; León, R; López, MG; Navarro, E; Negredo, P; Parada, E | 1 |
3 other study(ies) available for galantamine and okadaic acid
Article | Year |
---|---|
Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Calcium; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytotoxins; Electron Transport Chain Complex Proteins; Electrophorus; Glucose; Hippocampus; Humans; Isomerism; Models, Molecular; Naphthyridines; Neuroprotective Agents; Okadaic Acid; Oligomycins; Oxygen; Peptide Fragments; Protein Binding; Protein Phosphatase 2; Rats; Rotenone; Structure-Activity Relationship | 2010 |
Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.
Topics: Aconitine; Amyloid beta-Peptides; Apoptosis; Benzopyrans; Cell Culture Techniques; Cell Line, Tumor; Cholinesterase Inhibitors; Chromones; Donepezil; Dose-Response Relationship, Drug; Enzyme Inhibitors; Galantamine; Humans; Indans; L-Lactate Dehydrogenase; Morpholines; Neuroblastoma; Neuroprotective Agents; Nicotine; Nitriles; Okadaic Acid; Phenylcarbamates; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Nicotinic; Rivastigmine | 2005 |
Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Antioxidants; Cell Death; Galantamine; Hippocampus; Melatonin; Models, Biological; Neuroprotective Agents; Okadaic Acid; Phosphorylation; Protein Aggregates; Rats, Sprague-Dawley; tau Proteins; Tissue Culture Techniques | 2016 |